Novel Agents in CML Therapy:Tyrosine Kinase Inhibitors and Beyond-Junia V. Melo;Charles Chuah

Melo (2) and Charles Chuah (1)
1 Division of Haematology, Institute of Medical & Veterinary Science, Adelaide SA, Australia
2 Department of Haematology, Singapore General Hospital; Cancer and Stem Cell Biology Program,
Duke-NUS Graduate Medical School, Singapore.

Without doubt, imatinib represents a major achievement
for the treatment of CML but resistance to this drug has
become and will continue to be a therapeutic challenge.
Single agent therapy with imatinib may not be the best
long-term option in CML, at least for a proportion of patients,
and other strategies need to be explored. Many novel
compounds are currently being investigated preclinically
and clinically, and therapeutic approaches to circumvent
the problem of imatinib resistance are now possible.
Dasatinib and nilotinib represent the first of the newer generation
TKIs which are effective and safe in patients with
imatinib-resistant and -intolerant CML.

.....read pdf here